Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan

BOUDRY, Switzerland & TOKYO--(Healthcare Sales & Marketing Network)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (CELG) today announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally... Biopharmaceuticals, Oncology, RegulatoryCelgene, REVLIMID, lenalidomide, multiple myeloma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news